NEW
siPORTer-96 Electroporation Chamber
High Throughput siRNA Electroporation
• Efficient siRNA delivery with minimal cell mortality
• Electroporate up to 96 samples at the same time
• Deliver siRNA into primary, hard-to-transfect, and suspension cells
• Does not require expensive, consumable electroplates or cuvettes
• Use with Bio-Rad Gene Pulser Xcell pulse generator
Electroporation: An Advantageous Alternative to Chemical Transfection
Human primary cells are often preferred for RNAi experiments because they are more similar to their in vivo counterparts than are immortalized cells. Although common chemical transfection methods are effective in many transformed cell lines, they are often not effective for primary cells [1]. For these cell types as well as suspension and other hard-to-transfect cells, electroporation is a valuable alternative.
Electroporation involves applying an electric field pulse to induce the formation of microscopic pores in the cell membrane. These pores allow nucleic acids such as siRNA to traverse the membrane. Under specific pulse conditions, the pores reseal, and the electroporated cells recover and resume growth.
The siPORTer-96
Electroporation Chamber (patent pending; Figure 1) works with the Bio-Rad Gene Pulser Xcell pulse generator to allow high throughput siRNA electroporation. The specially designed electrodes enable rapid electroporation without requiring expensive, consumable electroplates or cuvettes. When you use the siPORTer-96 Electroporation Chamber to deliver siRNA, you will be able to detect RNAi-induced gene silencing just a few hours after delivery [2] (also, see Deliver siRNAs Into Primary Cells).
|
| Figure 1. siPORTer™-96 Electroporation Chamber. This photograph shows the electroporation chamber base with the electrode cartridge. The siPORTer-96 Electroporation Chamber was designed for safety and convenience. The assembled electrode cartridge protects samples from contamination--samples can be loaded inside a laminar flow hood, and the assembled electrode cartridge can be carried to the electroporation chamber base. Alternatively, the entire device can be set up inside a laminar flow hood. |
Greater Cell Viability
Most existing electroporation protocols were developed to deliver plasmid DNA into cell nuclei. These protocols often result in high rates of cell mortality. Since siRNAs need only be delivered into the cytoplasm, milder electroporation conditions can be used. Using milder electroporation conditions and siPORT siRNA
Electroporation Buffer (included) minimizes cellular mortality
and trauma without sacrificing efficient siRNA delivery [2].
With electroporation, transfection occurs immediately, and cells
can be transfected regardless of their cell cycle stage.
High Throughput, Reproducible Results
A multiwell electroporator makes optimizing electroporation conditions for new cell types much easier than single well electroporators. In addition, high throughput electroporation of siRNA libraries into primary cells is an extremely effective research tool for investigating gene function across entire gene classes. The siPORTer-96 Electroporation Chamber allows screening of large numbers of siRNAs rapidly, reproducibly, and in parallel. Using the same pulse conditions in a single run, other parameters can be identical or varied across wells. The standard sample volume is just under 50 µl, and as few as 2.5 x 104 cells can be used per reaction. This means that ~100 siRNAs could be screened using only 2.5 x 106 cells and 4.4 ml of siPORT siRNA Electroporation Buffer.
The siPORTer-96 Electroporation Chamber yields
results that are remarkably reproducible (Figure 2). 96 samples
were electroporated using identical conditions. Half of the samples
received an siRNA targeting GAPDH (Silencer® GAPDH
siRNA, Cat# 4605), and half received a scrambled Negative
Control siRNA (Silencer® Negative
Control #1 siRNA,
Cat# 4611). Data are shown for the GAPDH siRNA-treated samples.
Normal expression levels of GAPDH were reduced by a mean of 94.8%
with a coefficient of variance of 18.9%. Variability is attributed
to steps in the procedure such as pipetting error, measurement
error, and assay error, as well as true biological variability.
 |
| Figure 2. Reduction
of GAPDH Gene Expression in NHDF-neo Cells. siRNA
(1 µg) was electroporated into NHDF-neo (normal
numan dermal fibroblast cells, an adherent primary cell
type) using the siPORTer-96 Electroporation Chamber.
Samples 1-48 were transfected with an siRNA targeting
GAPDH (Silencer® GAPDH siRNA, this
figure), and samples 49-96 were transfected with
a negative control siRNA (Silencer® Negative
Control #1 siRNA, data not shown). 48 hours after transfection,
the cells were harvested and analyzed by real-time RT-PCR
for GAPDH expression levels. 18S rRNA levels were used
to normalize GAPDH expression. Remaining Gene Expression
was calculated as a percentage of GAPDH gene expression
compared with the averaged value from cells transfected
with the negative control siRNA. |
Figure 3 shows results of experiments used to identify optimal electroporation conditions for NHDF-neo primary cells. An siRNA targeting GAPDH and a Negative Control siRNA were again used for this experiment. Both remaining GAPDH expression levels and cell viability were measured. These data illustrate the impressive gene silencing that can be achieved by delivering a potent siRNA with the siPORTer-96 Electroporation Chamber while maintaining cell viability. A wide range of parameters are effective in delivering siRNA to adherent cells like NHDF-neo cells.
| |
 |
| Figure 3. GAPDH
Gene Silencing and Cell Viability Under Various Electroporation
Conditions. siRNA
(1 µg) targeting GAPDH (Silencer® GAPDH
siRNA, Ambion) or a Negative Control siRNA (Silencer® Negative
Control #1 siRNA, Ambion) were electroporated into normal
human dermal fibroblast cells (an adherent primary cell
type) using the siPORTer-96 Electroporation Chamber.
Four samples were electroporated at a time, either with
an siRNA targeting GAPDH (two samples) or with the negative
control siRNA (two samples). The voltage was varied between
200 and 600 V for either 250 or 400 µsec as labeled.
24 hours after electroporation, the cells were harvested
and analyzed by real-time RT-PCR for GAPDH expression
levels. 18S rRNA levels were used to normalize GAPDH
expression. Remaining Gene Expression was calculated
as a percentage of GAPDH gene expression compared with
samples transfected with the negative control siRNA (bars).
Cell viability was measured with ViaCount® Cell
Viability assay (Guava®) (diamonds). |
Summary
When used with Bio-Rad's Gene Pulser Xcell pulse generator, Ambion's siPORTer-96 Electroporation Chamber enables efficient high throughput electroporation of siRNA. Coupled with the siPORT siRNA Electroporation Buffer, the electroporator provides highly efficient siRNA delivery into primary and other hard-to-transfect cell types with minimal cell mortality. Standard sample volume is 44 µl, and enough siPORT siRNA Electroporation Buffer (12 X 1.5 ml) is supplied with the siPORTer-96 Electroporation Chamber for 360 samples. Conditions can be identical or varied across samples, and multiple wells allow for faster condition optimization. There is no need for expensive, disposable electrode plates or cuvettes. The unit is simply wiped with ethanol to clean.
Scientific Contributors
Dmitriy Ovcharenko, Rich Jarvis, Po-Tsan Ku, Kevin Kelnar, Vince Pallotta, Scott Hunicke-Smith • Ambion, Inc.
|